

# **Contents**

	<b>Page</b>
<b>Introduction and Aim of the work</b>	1-2
<b>Review of literature</b>	
• Cell cycle and its regulation.	3
• Apoptosis .	10
• Fas/Apo-1 / CD 95.	43
• Some aspects of acute lymphoblastic leukemia.	47
• Acute lymphoblastic leukemia, apoptosis and sFas / CD 95 / Apo-1.	71
<b>Subjects and methods</b>	74
<b>Results</b>	92
<b>Discussion</b>	136
<b>Summary &amp; conclusion</b>	150
<b>Recommendation</b>	155
<b>References</b>	156
<b>Arabic summary</b>	1

## **LIST OF TABLES**

	<b>Table</b>	<b>Page</b>
<b>I</b>	: Types of cell death, differential characteristics.	11
<b>II</b>	: Proteins of the Bcl-2 family.	25
<b>III</b>	: Diseases associated with induction and inhibition of apoptosis.	31
<b>IV</b>	: FAB classification of acute lymphoblastic leukemias.	54
<b>V</b>	: Cytochemistry of acute leukemia.	56
<b>VI</b>	: Immunophenotyping of ALL cells-ALL of B lineage.	59
<b>VII</b>	: Immunophenotyping of ALL cells - ALL of T lineage.	59
<b>VIII</b>	: MIC classification of acute lymphoblastic leukemia.	61
<b>IX</b>	: Chromosomal abnormalities in acute lymphoblastic leukemia.	63
<b>X</b>	: Definition of CNS disease status at diagnosis based on CSF finding.	66
<b>XI</b>	: Prognostic factors in ALL.	70
<b>XII</b>	: Preparation of TdT incubation buffer for experimental and positive control reactions.	81
<b>1</b>	: Sex distribution in 30 children with ALL.	92
<b>2</b>	: Age distribution in 30 children with ALL.	94
<b>3</b>	: Presenting symptoms in 30 children with ALL diagnosis.	96
<b>4</b>	: Frequency of physical signs in 30 children with ALL.	98
<b>5</b>	: Total leucocytic count in 30 children with ALL.	100
<b>6</b>	: Haemoglobin level in 30 children with ALL.	102
<b>7</b>	: Platelets count in 30 children with ALL.	104
<b>8</b>	: FAB classification in 30 children with ALL.	106

	<b>Table</b>	<b>Page</b>
9	: Immunophenotyping in 30 children with ALL.	108
10	: Other laboratory data of studied children with ALL.	110
11	: Comparison between cases before therapy and control group regarding mean TLC, Hb and platelets count and LDH level.	111
12	: Comparison between mean TLC in the studied cases before treatment, 1 day and 1 month after therapy.	113
13	: Comparison between mean Hb level in the studied cases before, after 1 day and 1 month after therapy.	115
14	: Comparison between mean platelets count of the studied cases before, 1 day and 1 month after therapy.	117
15	: Comparison between mean number of blast cells in peripheral blood in the studied cases before treatment, 1 day and 1 month after therapy.	119
16	: Comparison between mean bone marrow blast cells count in the studied patients before treatment and after the end of induction therapy.	121
17	: Comparison between mean percentage of apoptotic cells in the studied cases before therapy and 1day after induction therapy.	123
18	: Correlation between apoptosis & other prognostic variables.	125
19	: Comparison between mean serum level of sFas in patients of ALL before therapy and control group.	126
20	: Comparison between mean serum level of sFas in the studied cases before therapy, 1 day and one month after therapy.	128

<b>21 :</b>	Distribution of 30 children with ALL according to risk factors.	130
<b>22 :</b>	Comparison between serum sFas level in low and high risk groups ALL children.	131
<b>23 :</b>	Correlation between serum sFas level & prognostic factors at diagnosis.	133
<b>24 :</b>	Results of induction therapy in 30 children with ALL.	134